Formal nod for Eisai's Halaven in Japan
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has granted formal final regulatory approval to Eisai's novel anticancer agent Halaven (eribulin mesylate) for use in breast cancer.